BIOMAX INFORMATICS AG

Their core work

Biomax Informatics is a German SME that builds knowledge management and data integration platforms for life sciences, nanosafety, and neuroscience research. Their core business is turning complex, multi-source scientific data into structured, searchable knowledge — connecting databases, analytics tools, and domain-specific ontologies into unified platforms. They provide the informatics backbone that lets large research consortia actually make sense of their data, whether that's nanomaterial safety profiles, brain simulation outputs, or clinical biomarker discoveries.

What they specialise in

How they've shifted over time

In the early period (2015-2018), Biomax split its attention between nanosafety informatics and neuroscience/HPC infrastructure, establishing itself as a versatile data platform provider across two very different domains. From 2019 onward, the nanoinformatics work deepened significantly — moving from basic data curation to predictive toxicology, nanomaterial fingerprinting, and cloud-based regulatory tools — while a new thread in personalized medicine and chemical risk assessment emerged. The trajectory shows a company moving from general-purpose knowledge management toward domain-specific predictive analytics platforms, particularly in safety and regulatory science.

Biomax is converging toward regulatory science platforms — expect them to pursue projects where complex safety/risk data needs to be integrated, modelled, and made accessible to regulators.

How they like to work

Biomax overwhelmingly operates as a participant (7 of 9 projects), joining large RIA consortia where they contribute a specific informatics platform capability. They coordinated once — a small SME Instrument Phase 1 project (BrainBase) — suggesting they prefer to embed their technology into bigger initiatives rather than lead them. With 239 unique partners across 31 countries, they are a high-connectivity node: the kind of partner that brings integration expertise without competing for scientific leadership.

Biomax has collaborated with 239 unique partners across 31 countries, giving them one of the broadest partner networks you'd expect from an SME of this size. Their connections span nanosafety, neuroscience, and biomedical research communities across nearly all EU member states.

What sets them apart

Biomax occupies a rare niche: they are a commercial software company that has embedded itself deeply into EU research infrastructure projects, not as a generic IT provider but as a domain-aware knowledge management specialist. Their ability to work across completely different scientific domains — from brain simulation to nanomaterial toxicology to personalized medicine — while providing the same core data integration value is unusual. For consortium builders, they solve the perennial problem of "we have data from 15 partners in different formats and need it in one place."

Highlights from their portfolio

• NanoCommons
  Their largest funded project (EUR 296,500), building the European nanotechnology community informatics platform — a flagship infrastructure role.
• HBP SGA3
  Part of the Human Brain Project, one of the EU's largest research initiatives, contributing to the EBRAINS research infrastructure for neuroscience.
• BrainBase
  Their only coordinated project — an SME Instrument Phase 1 exploring commercial potential of a brain data knowledge management platform.